Related Experiment Video
Updated: Jul 12, 2025
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors
Alaa Alsalloum1,2, Saleh Alrhmoun1,2, Julia Shevchenko1
1Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk 630099, Russia.
Abstract:
Adoptive T-cell therapies tailored for the treatment of solid tumors encounter intricate challenges, necessitating the meticulous selection of specific target antigens and the engineering of highly specific T-cell receptors (TCRs). This study delves into the cytotoxicity and functional characteristics of in vitro-cultured T-lymphocytes, equipped with a TCR designed to precisely target the cancer-testis antigen NY-ESO-1. Flow cytometry analysis unveiled a notable increase in the population of cells expressing activation markers upon encountering the NY-ESO-1-positive tumor cell line, SK-Mel-37. Employing the NanoString platform, immune transcriptome profiling revealed the upregulation of genes enriched in Gene Ontology Biological Processes associated with the IFN-γ signaling pathway, regulation of T-cell activation, and proliferation. Furthermore, the modified T cells exhibited robust cytotoxicity in an antigen-dependent manner, as confirmed by the LDH assay results. Multiplex immunoassays, including LEGENDplex™, additionally demonstrated the elevated production of cytotoxicity-associated cytokines driven by granzymes and soluble Fas ligand (sFasL). Our findings underscore the specific targeting potential of engineered TCR T cells against NY-ESO-1-positive tumors. Further comprehensive in vivo investigations are essential to thoroughly validate these results and effectively harness the intrinsic potential of genetically engineered T cells for combating cancer.
Insights
Engineered T cells targeting the NY-ESO-1 antigen show promise for solid tumor treatment. These T cells demonstrated specific activation, proliferation, and cancer cell killing in vitro.
Area of Science:
- Immunology
- Oncology
- Cell Therapy
Background:
- Adoptive T-cell therapies for solid tumors face challenges in antigen selection and T-cell receptor (TCR) engineering.
- NY-ESO-1 is a cancer-testis antigen recognized as a potential target for cancer immunotherapy.
Purpose of the Study:
- To evaluate the efficacy and functional characteristics of T-lymphocytes engineered with a TCR targeting the NY-ESO-1 antigen.
- To assess the in vitro cytotoxicity and immune response of these engineered T cells against NY-ESO-1-positive tumor cells.
Main Methods:
- T-lymphocytes were engineered with a TCR specific for NY-ESO-1.
- Flow cytometry was used to analyze T-cell activation markers.
- NanoString platform was employed for immune transcriptome profiling.
- Lactate dehydrogenase (LDH) assay and multiplex immunoassays (LEGENDplex™) were used to assess cytotoxicity and cytokine production.
Main Results:
- Engineered T cells showed increased activation markers when co-cultured with NY-ESO-1-positive tumor cells (SK-Mel-37).
- Transcriptome analysis revealed upregulation of genes in IFN-γ signaling, T-cell activation, and proliferation pathways.
- Antigen-dependent cytotoxicity was confirmed via LDH assay.
- Elevated production of granzymes and soluble Fas ligand (sFasL) was observed.
Conclusions:
- Engineered TCR T cells exhibit specific targeting capabilities against NY-ESO-1-positive solid tumors.
- These findings support further in vivo studies to validate the therapeutic potential of these engineered T cells for cancer treatment.
More Related Videos
10:01Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes
Published on: February 11, 2015
06:10Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
